Madrigal PharmaceuticalsMIL:1MDGL 8 Beneish M-Score is 1.29 as of Jun. 26, 2026, which is 53% below its 10-year median of 2.72. GuruFocus rates MIL:1MDGL with a GF Score™ of 8/100. The stock has 4 warning signs investors should review. Among 831 Biotechnology companies, Madrigal Pharmaceuticals ranks worse than 87.61% on this metric.
The zones of discrimination for M-Score is as such:
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Warning Sign:
Beneish M-Score 1.29 higher than -1.78, which implies that the company might have manipulated its financial results.
The historical rank and industry rank for Madrigal Pharmaceuticals's Beneish M-Score or its related term are showing as below:
MIL:1MDGL'
s Beneish M-Score Range Over the Past 10 Years
Min: 0.49 Med: 2.72 Max: 27.58
Current: 1.29
During the past 13 years, the highest Beneish M-Score of Madrigal Pharmaceuticals was 27.58. The lowest was 0.49. And the median was 2.72.
Madrigal Pharmaceuticals Beneish M-Score Related Terms
Madrigal Pharmaceuticals Beneish M-Score Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIL:1MDGL vs BMRN, ARWR, AXSM: Beneish M-Score Comparison
For the Biotechnology subindustry, Madrigal Pharmaceuticals's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Madrigal Pharmaceuticals Beneish M-Score vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Madrigal Pharmaceuticals's Beneish M-Score distribution charts can be found below:
* The bar in red indicates where Madrigal Pharmaceuticals's Beneish M-Score falls into.
The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.
The M-Score Variables:
The M-score of Madrigal Pharmaceuticals for today is based on a combination of the following eight different indices:
M
=
-4.84
+
0.92 * DSRI
+
0.528 * GMI
+
0.404 * AQI
+
0.892 * SGI
+
0.115 * DEPI
=
-4.84
+
0.92 * 0.8657
+
0.528 * 1.0381
+
0.404 * 5.3878
+
0.892 * 3.2948
+
0.115 * 2.5805
-
0.172 * SGAI
+
4.679 * TATA
-
0.327 * LVGI
-
0.172 * 0.4919
+
4.679 * -0.027767
-
0.327 * 1.9418
=
1.07
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.
DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.
DEPI
=
(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1))
/
(Depreciation_t / (Depreciaton_t + PPE_t))
=
(1.214 / (1.214 + 3.71))
/
(1.301 / (1.301 + 12.316))
=
0.246548
/
0.095542
=
2.5805
Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.
6. SGAI = Sales, General and Administrative expenses Index
Total accruals calculated as the change in working capital accounts other than cash less depreciation.
TATA
=
(IncomefromContinuingOperations_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(NetIncome_t - NonOperatingIncome_t
-
CashFlowsfromOperations_t)
/
TotalAssets_t
=
(-265.619 - -4.572
-
-231.568)
/
1061.638
=
-0.027767
An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.
Madrigal Pharmaceuticals has a M-score of 1.07 signals that the company is likely to be a manipulator.
Madrigal Pharmaceuticals (MIL:1MDGL) has a Beneish M-Score of 1.29 as of Jun. 26, 2026. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Madrigal Pharmaceuticals and its competitors. This is 53% below median its historical median of 2.72. Over the past decade, Madrigal Pharmaceuticals' Beneish M-Score has ranged from 0.49 to 27.58. According to the industry distribution chart, Madrigal Pharmaceuticals ranks #728 out of 831 companies in the Biotechnology industry, placing it in the top 87.6%.
Is Madrigal Pharmaceuticals' Beneish M-Score too high?
Madrigal Pharmaceuticals' current Beneish M-Score of 1.29 is 53% below median its 10-year median of 2.72. Over the past 10 years, this metric has ranged from a low of 0.49 to a high of 27.58. Based on the distribution chart, Madrigal Pharmaceuticals ranks #728 out of 831 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Madrigal Pharmaceuticals has a GF Score™ of 8/100, reflecting its overall financial health beyond just this single metric.
How does Madrigal Pharmaceuticals' Beneish M-Score compare to BMRN and ARWR?
According to the Biotechnology industry distribution chart, Madrigal Pharmaceuticals ranks #728 out of 831 companies for Beneish M-Score. This places Madrigal Pharmaceuticals in the lower half of its industry. Historically, Madrigal Pharmaceuticals' own Beneish M-Score has ranged from 0.49 to 27.58 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beneish M-Score for a Biotechnology company?
A good Beneish M-Score depends on the Biotechnology industry context. However, Beneish M-Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beneish M-Score mean?
A high Beneish M-Score can signal that a stock is expensive relative to its fundamentals. The Beneish M-score measures the likelihood of earnings manipulation. View historical data on Madrigal Pharmaceuticals and its competitors. Madrigal Pharmaceuticals's current Beneish M-Score is 1.29, which is 53% below median its own 10-year median of 2.72. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Madrigal Pharmaceuticals stock overvalued right now?
Madrigal Pharmaceuticals (MIL:1MDGL) has a current Beneish M-Score of 1.29. The current Beneish M-Score is 1.29, which is 53% below median its 10-year median of 2.72. Madrigal Pharmaceuticals' overall GF Score™ is 8/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beneish M-Score calculated?
Beneish M-Score is calculated from a company's financial statements. For Madrigal Pharmaceuticals (MIL:1MDGL), the current Beneish M-Score is 1.29 as of Jun. 26, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, liver cancer, need for liver transplantation and premature mortality. Its medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor beta agonist designed to target key underlying causes of MASH.
8GF Score
Get the complete analysis for MIL:1MDGL
Beneish M-Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIL:1MDGL has been successfully added to your 
